New Products Will Force 'Radical Shift' in Hemophilia Drug Market
The hemophilia treatment landscape is to undergo a radical shift away from established short-acting therapies, beginning with the launch of Biogen Idec’s long-acting rFVIII and rFIX products this year, according to research and consulting firm GlobalData.
The hemophilia treatment landscape is to undergo a radical shift away from established short-acting therapies, beginning with the launch of Biogen Idec’s long-acting rFVIII and rFIX products this year, according to research and consulting firm GlobalData.
The GlobalData report states that the patient shares of currently marketed short-acting recombinant products will erode considerably by 2022 across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan).
Brooke Baker, Ph.D., Senior Analyst at GlobalData, says: “Biogen Idec’s new treatments have the potential to reduce the number of weekly prophylactic infusions and greatly improve patients’ convenience and quality of life. By pricing its long-acting agents, namely Eloctate and Alprolix, in line with the established short-acting recombinant factors, [the company] aims to incentivize patients to switch from their previous therapies.”
GlobalData forecasts that peak-year US sales for Eloctate and Alprolix will reach $786 million and $349 million by 2022, respectively.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
